KLRK1 and neoplasm: Analogously, in a xenogeneic ovarian carcinoma model, it has been demonstrated that the chemotherapeutic drug gemcitabine increased the expression of NKG2D ligands and death receptors on tumor cells, and the adoptive transfer of NK cells in combination with gemcitabine additively decreased ovarian cancer growth (145).